600 patients66,869 observations120 daysLIVE

Patient P-01373

Synthetic patientNBL-101 · Day 92 · 25–34 · M · baseline S12Open companion preview
Therapy response
Favorable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S12
  2. Day 82 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 82 GI-04 recommendedGI Support Protocol GI-04
  4. Day 83 Patient declinedNot now

What changed?

Trajectory began diverging from predicted response on Day 82.

Primary contributors, last 14 days
  • GI instability+43
  • Inflammatory activity+41
  • Toxicity+32
  • Nutritional resilience-23
  • Treatment adherence-8

What helped?

  • GI Support Protocol GI-04Day 82
    Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
65%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 86% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 67
  • Mucosal barrier integrity 60
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 71 and rising
    • WearableSleep 5.7 h, below personal baseline
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 37/100
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 40
    • Wearable300 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 50
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Rapid metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.1 · butyrate capacity 37/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
47 ms
Sleep
6.1 h
Steps
2,024
Resting HR
62 bpm
Daily log: GI score 71, nutritional resilience 32, adherence 81.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0186049%S2062
P-0138837%S17CR-01improved59
P-0137136%S06CR-01improved63
P-0176836%S2053
P-0145935%S0251
P-0132134%S12GI-04improved53
P-0169633%S20CR-01improved59
P-0169933%S04GI-04improved69
P-0136232%S2060
P-0171531%S0556
P-0183531%S17CR-01improved56
P-0144230%S13CR-01improved61